MRRS adds "Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia – high blood glucose levels – that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Table of Contents
3 Marketed Products 43
3.1 Overview 43
3.2 Biguanides 44
3.2.1 Metformin 44
3.3 Sulfonylureas 45
3.4 Thiazolidinediones 47
3.4.1 Pioglitazone 47
3.5 GLP-1 receptor agonists 48
3.5.1 Byetta (exenatide) 48
3.5.2 Bydureon (exenatide) 49
3.5.3 Victoza (liraglutide) 50
3.5.4 Lyxumia (lixisenatide) 51
3.5.5 Tanzeum (albiglutide) 53
3.5.6 Trulicity (dulaglutide) 54
3.6 DPP-4 Inhibitors 55
3.6.1 Januvia/Glactiv (sitagliptin) 55
3.6.2 Galvus (vildagliptin) 56
3.6.3 Onglyza (saxagliptin) 57
3.6.4 Trazenta (linagliptin) 58
3.6.5 Zafatek (trelagliptin succinate) 59
3.6.6 Marizev (omarigliptin) 60
3.7 SGLT-2 Inhibitors 61
3.7.1 Forxiga (dapagliflozin) 61
3.7.2 Invokana (canagliflozin) 62
3.7.3 Jardiance (empagliflozin) 63
3.8 Insulin Therapies 63
3.8.1 Lantus (insulin glargine) 63
3.8.2 Levemir (insulin detemir) 64
3.8.3 Tresiba (insulin degludec) 65
3.8.4 Toujeo/ Lantus XR (insulin glargine) 66
3.9 Marketed Products Heat Maps 67
4 Pipeline 70

List of Tables and Figures 
Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy 27
Table 2: T2DM Therapeutics Market, Global, Breakdown of Multiple Molecular Targets, 2015 77
Table 3: T2DM Therapeutics Market, Global, Breakdown of ‘‘Other’’ Molecular Targets, 2015 78
Table 4: T2DM Therapeutics, Global, All Pipeline Products, Discovery Phase, 2015 129
Table 5: T2DM Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2015 132
Table 6: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed Phase, 2015 140
Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase I, 2015 141
Table 8: T2DM Therapeutics, Global, All Pipeline Products, Phase II, 2015 143
Table 9: T2DM Therapeutics, Global, All Pipeline Products, Phase III, 2015 145
Table 10: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015 145
Table 11: T2DM Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021 146
Figure 1: T2DM Therapeutics Market, Global, Heat Map for Marketed Products, 2015 68
Figure 2: T2DM Therapeutics Market, Global, Heat Map for Marketed Products, 2015 (continued) 69
Figure 3: T2DM Therapeutics Market, Global, Pipeline, 2015 71
Figure 4: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2015 73
Figure 5: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of GPCR Molecular Targets, 2015 74
Figure 6: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Protein Kinase Molecular Targets, 2015 75
Figure 7: T2DM Therapeutics Market, Global, Clinical Trial Failure Rates and Reasons for Failure, 2006-2015 80...

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-markets-to-2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/